glutamate ionotropic receptor delta type subunit 1Genealiases: GluD1 · GluD1-b
Q-omics provides the consensus-scored GRID1 profile across patient tissues and cancer cell-line models. GRID1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GRID1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, GRID1 RNA expression shows 17,302 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, KIRC, and BRCA as cancer lineages where GRID1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRID1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRID1 survival associations across molecular data types. GRID1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRID1 RNA expression–survival associations across cancer types. High GRID1 expression shows unfavorable associations in UVM, KIRP, OV and STAD, but favorable associations in LGG and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GRID1 RNA expression.
This table summarizes GRID1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GRID1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRID1 shows lower tumor expression in LUAD, THCA, KICH and LUSC and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher GRID1 RNA expression in tumor versus normal tissue (log2 FC = +0.719, t-test p < 0.001).
This table shows molecular features associated with GRID1 in patient tissues and cancer cell lines. In patient samples, GRID1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, GRID1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
